Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Safety × Plasma cell × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1 Plasma cell 1 Other solid neoplasm 1 Other hematologic neoplasm 1 Breast 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 755 Bortezomib 419 Lenalidomide 405 Cyclophosphamide 324 Melphalan 252 Calcium Dobesilate 226 daratumumab 207 pomalidomide 178 carfilzomib 158 fludarabine 120 fludarabine phosphate 113 Thalidomide 107 Peripheral Blood Stem Cell Transplantation 104 Filgrastim 102 ixazomib 84 Whole-Body Irradiation 78 dexamethasone acetate 76 Granulocyte Colony-Stimulating Factor 76 Busulfan 74 Mycophenolic Acid 73 Tacrolimus 64 dexamethasone 21-phosphate 62 Prednisone 59 auricularum 57 Cyclosporine 56 isatuximab 55 belantamab mafodotin 55 elotuzumab 53 Antilymphocyte Serum 48 Radiotherapy 46

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02786511 2020-01-22

Longterm Follow-up of Subjects Treated With bb2121

Celgene

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡